2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus
Arthritis & Rheumatology · 2026-07 · 78 (7) · 1361-1386
DOI: 10.1002/art.43452 ↗Kurz gefasst
Leitlinie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 04.11.2025. Verfasst von Lisa R Sammaritano und 47 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Special Surgery Weill Cornell Medicine, New York, New York. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Immunosuppressive Agents, Antirheumatic Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS.
Abstract (Originalsprache)
Objective
To provide evidence‐based and expert guidance for the treatment and management of non‐renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline.
Methods
Clinical questions for treatment and management of SLE were developed in the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were developed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess evidence quality and formulate recommendations. The Voting Panel achieved a consensus of ≥70% agreement on the direction (for or against) and strength (strong or conditional) of each recommendation.
Results
We present recommendations and ungraded, consensus‐based good practice statements for the treatment and management of SLE that are applicable to pediatric and adult patients. Recommendations emphasize uniform treatment with hydroxychloroquine, limiting duration of glucocorticoid use, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve and maintain control of SLE inflammation (remission or a low level of disease activity), reduce SLE‐related morbidity and mortality, and minimize medication‐related toxicities.
Conclusion
This guideline presents direction regarding treatment and management of SLE and provides a foundation for well‐informed, shared clinician–patient decision‐making. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each person with SLE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital for Special Surgery Weill Cornell Medicine, New York, New York.
- Columbia University, New York, New York.
- University of Texas Southwestern Medical Center, Dallas.
- University of California, San Francisco.
- Mayo Clinic, Rochester, Minnesota.
- The Hospital for Sick Children, Toronto, Ontario, Canada.
ORCID-Profile: Lisa R Sammaritano, Anca Askanase, Bonnie L Bermas, Alí Duarte-García, Linda T Hiraki, Cynthia Aranow, April Barnado, Hermine I Brunner, Benjamin F Chong, Aimee O Hersh, Tamar B Rubinstein, Benjamin J Smith, Daniel J Wallace, Christie M Bartels, Kimberly DeQuattro, Gabriel Figueroa-Parra, Shivani Garg, Lais Lopes Almeida Gomes, April Jorge, Shanthini Kasturi, Hassan Kawtharany, Kimberly P Liang, Megan M Lockwood, Alain Sanchez-Rodriguez, Jessica N Williams, Amy S Turner
Förderung
- NIAMS NIH HHS
Zitieren
APA
Sammaritano, L. R., Askanase, A., Bermas, B. L., Dall'Era, M., Duarte-García, A., Hiraki, L. T., Son, M. B. F., Werth, V. P., Aranow, C., Barnado, A., Broder, A., Brunner, H. I., Chong, B. F., Chowdhary, V. R., Hersh, A. O., Izmirly, P. M., Jules, M., Kalunian, K., Kamen, D., …, & Mustafa, R. A. (2026). 2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis & Rheumatology, 78(7), 1361-1386. https://doi.org/10.1002/art.43452
Vancouver
Sammaritano LR, Askanase A, Bermas BL, Dall'Era M, Duarte-García A, Hiraki LT, et al. 2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2026;78(7):1361-1386. doi:10.1002/art.43452
BibTeX
@article{Sammaritano2026,
author = {Sammaritano, Lisa R and Askanase, Anca and Bermas, Bonnie L and Dall'Era, Maria and Duarte-García, Alí and Hiraki, Linda T and Son, Mary Beth F and Werth, Victoria P and Aranow, Cynthia and Barnado, April and Broder, Anna and Brunner, Hermine I and Chong, Benjamin F and Chowdhary, Vaidehi R and Hersh, Aimee O and Izmirly, Peter M and Jules, Marimee and Kalunian, Kenneth and Kamen, Diane and Rubinstein, Tamar B and Smith, Benjamin J and Smith, Natalie M and Thomas, Asha and Timlin, Homa and Wallace, Daniel J and Azzam, Muayad and Bartels, Christie M and Cunha, Joanne S and DeQuattro, Kimberly and Fava, Andrea and Figueroa-Parra, Gabriel and Garg, Shivani and Gomes, Lais Lopes Almeida and Cuéllar-Gutiérrez, Maria C and Iyer, Priyanka and Johannemann, Andrew S and Jorge, April and Kasturi, Shanthini and Kawtharany, Hassan and Khawandi, Jana and Legge, Alexandra and Liang, Kimberly P and Lockwood, Megan M and Sanchez-Rodriguez, Alain and Turgunbaev, Marat and Williams, Jessica N and Turner, Amy S and Mustafa, Reem A},
title = {2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus},
journal = {Arthritis & Rheumatology},
year = {2026},
volume = {78},
number = {7},
pages = {1361--1386},
doi = {10.1002/art.43452}
}
EUVIMED